Table 2.

PTH primary and secondary efficacy outcomes

PTH Primary and Secondary OutcomesCinacalcet (n=155)Vitamin D Analog (n=157)Treatment
DifferenceOdds Ratio 
(95% CI)aP Valueb
Mean change in PTH between baseline and EAP, %−12.1 (−20.0 to −4.1)−7.0 (−14.9 to 0.8)−5.0 (−15.4 to 5.4)0.35
Participants with ≥30% reduction in plasma PTH from baseline to EAP66 (42.6)53 (33.8)8.80%1.45 (0.92 to 2.29)0.11
Participants achieving plasma PTH <300 pg/ml (assessed during EAP)30 (19.4)24 (15.3)4.10%1.33 (0.74 to 2.39)0.35
  • Data are presented as the mean (95% confidence interval) or n (%) unless otherwise indicated. PTH, parathyroid hormone; EAP, efficacy assessment phase; 95% CI, 95% confidence interval.

  • a Cochran–Mantel–Haenszel adjusted odds ratio (95% CI) for cinacalcet/vitamin D analog.

  • b P value for the difference between treatment arms for the primary study outcomes.